PEG sensitivity in HVTN 133 and a healthy control population (Healthy Volunteers)

Purpose of this Study

We are doing this study to learn more about how certain vaccines can affect people's polyethylene glycol (PEG) sensitivity levels. PEG is a component of several different vaccines. We want to compare blood samples from healthy volunteers to blood samples from HIV Vaccine Trials Network (HVTN) 133 participants. We hope this will help us better understand the variation of PEG sensitivity in the general population and between vaccinated and unvaccinated individuals.

Who Can Participate?

Eligibility

Adults ages 18-50 who:
  • Are in general good health
  • Are not pregnant or breastfeeding
  • Do not use any medications that can suppress the immune system
For more information about this study, please contact the study team at dvtustudies@duke.edu.

Age Range

18-50

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
Yes

What is Involved?

Description

If you choose to join this study, you will:
  • Visit our clinic up to 3 times over the course of about a month
  • Have a blood draw at each visit
Each visit for a blood draw will take 15-20 minutes, and we will collect 1-2 tablespoons of blood.

Locations

Other

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Assessing polyethylene glycol (PEG) sensitivity in participants enrolled in HVTN 133 and a healthy control population

Principal Investigator

Emmanuel
Walter

Protocol Number

PRO00116401

NCT ID

NA

Phase

N/A

Enrollment Status

Open to Enrollment
ClinicalTrials.gov